https://doi.org/10.55788/57ff5447
The randomised phase 3 iROC trial (NCT03049410) was designed to compare robotically assisted radical cystectomy with open radical cystectomy in patients with urothelial cell carcinoma (n=338; mean age 69 years). During the opening session of EAU 2022, Prof. James Catto (University of Sheffield, UK) presented the results of the trial. The number of days alive and out of hospital within 90 days of surgery (DAOH90) was the primary outcome of this study, including both the length of stay and readmissions.
The DAOH90 was significantly higher in the robotic surgery arm than in the open surgery arm (median 82 vs 80 days; P=0.01). Prof. Catto added that both the length of stay (median 7 vs 8 days; P=0.045) and the readmission rates (21.8% vs 32.2%; P=0.04) contributed to the favourable DAOH90 outcomes for patients in the robotic surgery arm.
Several quality-of-life measures indicated an improved quality of life 5 to 12 days after surgery for patients in the robotic surgery arm. However, 26 days after surgery, the quality-of-life outcomes were comparable for those who underwent robotic surgery and those who received open surgery.
Wound infections (5.6% vs 17.3%) and thromboembolic events (1.9% vs 8.3%) were more common in patients who underwent open surgery. There were no substantial differences in mortality rates (14.3% vs 14.7%; P=0.8) or cancer recurrence rates (18% vs 16%) between the 2 study arms.
Prof. Catto concluded that the iROC trial showed that robotic surgery may offer benefits over open surgery in patients with urothelial carcinoma, but that the clinical importance of the observed differences remains uncertain.
- Catto J, et al. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. Game-Changing Session 1, EAU 2022, 01–04 July.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Improved risk stratification for high-risk NMIBC Next Article
Darolutamide performs well across subgroups in mHSPC »
« Improved risk stratification for high-risk NMIBC Next Article
Darolutamide performs well across subgroups in mHSPC »
Table of Contents: EAU 2022
Featured articles
Darolutamide performs well across subgroups in mHSPC
Genitourinary Cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Functional Urology
Novel therapeutic targets for benign prostatic hyperplasia
Mini-slings non-inferior to standard mid-urethral slings in SUI
Non-inferiority of methenamine hippurate to antibiotics in recurrent UTIs
Related Articles
May 21, 2019
Penile prosthesis implantation
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com